Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Anticancer Research|April 3, 2020
PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell CarcinomaYohei Sekino, Takeshi Hagura, Xiangrui Han, et al.
Sexual Medicine|May 25, 2023
Long-term efficacy of penile rehabilitation with low-intensity extracorporeal shock wave therapy for sexual and erectile function recovery following robotic-assisted radical prostatectomy: a single-cohort pilot studyYuki Kohada, Takashi Babasaki, Keisuke Goto, et al.
Oncology Letters|July 12, 2014
Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapyJun Teishima, Kohei Kobatake, Tetsutaro Hayashi, et al.
International Cancer Conference Journal|June 26, 2020
Renal metastasis from primary hepatocellular carcinoma: a case reportRyoken Yamanaka, Yohei Sekino, Takashi Babasaki, et al.
Urologic Oncology|August 6, 2017
The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitorJun Teishima, Kohei Kobatake, Shunsuke Shinmei, et al.
Urologic Oncology|March 27, 2021
TUBB3 is associated with PTEN, neuroendocrine differentiation, and castration resistance in prostate cancerYohei Sekino, Xiangrui Han, Takashi Babasaki, et al.
BJU International|August 18, 2020
Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassificationYuki Kohada, Tetsutaro Hayashi, Ryan S Hsi, et al.
Oncology|June 26, 2020
TUBB3 Is Associated with High-Grade Histology, Poor Prognosis, p53 Expression, and Cancer Stem Cell Markers in Clear Cell Renal Cell CarcinomaYohei Sekino, Xiangrui Han, Takashi Babasaki, et al.
IJU Case Reports|August 4, 2020
Pneumatosis cystoides intestinalis linked to sunitinib treatment for renal cell carcinomaHiroyuki Shikuma, Shogo Inoue, Tomoya Hatayama, et al.
Current Urology|September 11, 2023
Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinomaJun Teishima, Daiki Murata, Kazuma Yukihiro, et al.
Pageof 10